Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “VACCINATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources

Vaccines for preventing cholera.

BACKGROUND: Oral cholera vaccines (either killed whole cell or live recombinant vaccines) are newer alternatives to the parenteral vaccines which have been thought to confer only moderate and short-term immunity. OBJECTIVES: The objective of this review was to assess the effect of cholera vaccines in preventing cases of cholera and preventing deaths. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register, Medline, Embase and reference lists of articles. We handsearched the journal Vaccine, contacted researchers in the field and manufacturers. SELECTION CRITERIA: Randomised and quasi-randomised studies comparing cholera vaccines (killed or live) with placebo, control vaccines or no intervention, or comparing types, doses or schedules of cholera vaccine. We included adults and children irrespective of immune status or special risk category. DATA COLLECTION AND ANALYSIS: Data extraction and assessment of trial quality was done independently by two reviewers. MAIN RESULTS: Thirty-two trials were included. Seventeen efficacy trials of relatively good quality, testing parenteral and oral killed whole cell vaccines and involving over 2. 6 million adults, children and infants were included. Nineteen safety trials have been conducted for both types of killed whole cell vaccines and for live vaccines and have involved 11,459 people. For all types of vaccines compared to placebo, the relative risk of contracting cholera at 12 months was 0.49, 95% confidence interval 0. 41 to 0.59 (random effects model). This translates to an efficacy of 51%, 95% confidence interval 41% to 59%. Both parenteral and oral administration were relatively efficacious, but significant protection extended into the third year for oral killed whole cell vaccines. Children under 5 were only protected for up to a year, while older children or adults were protected for up to three years. Parenteral killed whole cell vaccines were associated with increased systemic and local adverse effects compared to placebo. Oral killed whole cell vaccines or oral live vaccines were not. REVIEWER'S CONCLUSIONS: Cholera killed whole cell vaccines appear to be relatively effective and safe. Live oral recombinant vaccines appear to be safe, but efficacy data are not available. Protection against cholera appears to persist for up to two years following a single dose of vaccine, and for three to four years with an annual booster.

Adult↗

[Evaluation of vaccination programs through serological studies and distributed vaccines].

BACKGROUND: The objective of this study was to compare vaccination coverage in schoolchildren for the measles-mumps-rubella (MMR) and diphtheria-tetanus-pertussis (DTP) triple vaccines, and the poliomyelitis vaccine based on: a) vaccines distributed to vaccination centers; b) reported vaccination history, and c) serological analysis of antibodies. METHODS: Vaccination coverage was calculated on the basis of vaccination history collected by questionnaire, and by serological analysis of antibodies against measles for the MMR vaccine and against tetanus for the DTP vaccine in a representative sample of schoolchildren in 2001. The vaccination coverage from vaccination registries was obtained by dividing the number of individuals who could have completed their vaccinations by the target population. The concordance between the vaccination history and serological analysis was evaluated using the kappa test. RESULTS: The vaccination coverage obtained by questionnaire in schoolchildren aged 6-8 and 9-11 years was 85.5 and 87.6% for the DTP vaccine, 89.9 and 89.6% for the MMR vaccine, and 90.4 and 89.4% for the poliomyelitis vaccine, respectively, while the vaccination coverage obtained by serological analysis was 100 and 99.6% for the DTP vaccine and 85.5 and 93.3% for the MMR vaccine, respectively. The vaccination coverages obtained from distributed vaccines were significantly higher: 93.5 and 100% for the DTP vaccine, 96.3 and 98.8% for the MMR vaccine and 100% for the poliomyelitis vaccine. A low concordance was obtained between the vaccination history and serological analysis of antibodies (kappa < 0.2). CONCLUSION: Planning and evaluation of vaccination programs should be based on vaccination coverages obtained from serological analysis of antibodies in representative samples of schoolchildren.

Child↗